CTOs on the Move

Flower One

www.flowerone.com

 
Flower One is the largest cannabis cultivator, producer, and full-service brand fulfillment partner in the state of Nevada. By combining more than 20 years of greenhouse operational excellence with best-in-class cannabis operators, Flower One offers consistent, reliable, and scalable fulfillment to a growing number of industry-leading cannabis brands (Cookies, Kiva, Old Pal, Heavy Hitters, Lift Ticket`s, The Clear, and Flower One`s leading in-house brand, NLVO, and more). Flower One currently produces a wide range of products from flower, full-spectrum oils, and distillates to finished consumer packaged goods, including a variety of: pre-rolls, concentrates, edibles, topicals, and more for the top-performing ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.flowerone.com
  • 3950 North Bruce Street
    Las Vegas, NV USA 89030
  • Phone: 702.623.2919

Executives

Name Title Contact Details

Funding

Flower One raised $20.8M on 11/17/2019
Flower One raised $39M on 10/07/2020

Similar Companies

Gnosko Bio

Gnosko Bio is a medical and laboratory supply company based in Philadelphia, PA that provides real-time inventory management automation solutions for the biotech industry.

Natrol

Natrol, Inc. (Natrol) manufactures and markets dietary supplements, herbal teas, and sports nutrition products under three primary brands: Natrol, Laci Le Beau, and Prolab. Through its Essentially Pure Ingredients (EPI) division, the Company sells

Epic Technology Consulting

Epic Technology Consulting is a Villa Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canadian International Pharmacy Association

Canadian International Pharmacy Association is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.